Akzo Nobel confirms OBS sale on schedule

Amsterdam, the Netherlands, October 11, 2007 - Schering-Plough Corporation has received approval from the European Commission for its planned acquisition of Organon BioSciences N.V. from Akzo Nobel N.V. In connection with the clearance, Schering-Plough has agreed to divest certain animal health products in Europe. The divestitures are not material to the company's financial results. No divestitures of human health products are required. The EUR 11 billion deal was announced in March and Schering-Plough still needs to secure certain regulatory approvals, including clearance from the U.S. Federal Trade Commission (FTC), before the transaction can be finalized. Both Akzo Nobel and Schering-Plough continue to expect the deal to be completed by the end of the year. - - - Note to editors Akzo Nobel is a Fortune Global 500 company and is listed on Euronext Amsterdam. It is also the Chemicals Industry leader on the Dow Jones Sustainability Indexes and Akzo Nobel is included on the FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the third quarter will be published on October, 23, 2007. Internet: www.akzonobel.com Not for publication - for more information Akzo Nobel N.V. Corporate Media Relations, tel. +31 20 502 7833 Contact: Heleen van de Lustgraaf